Cargando…

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease

Detalles Bibliográficos
Autores principales:	Cavalli, Giulio, Tomelleri, Alessandro, De Luca, Giacomo, Campochiaro, Corrado, Dinarello, Charles A., Baldissera, Elena, Dagna, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388469/ https://www.ncbi.nlm.nih.gov/pubmed/30803447 http://dx.doi.org/10.1186/s13075-019-1850-x

Ejemplares similares

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Adult-onset Still’s disease complicated by Guillain-Barré syndrome
por: Farina, Nicola, et al.
Publicado: (2023)

Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
por: Cavalli, Giulio, et al.
Publicado: (2020)

Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey
por: Tomelleri, Alessandro, et al.
Publicado: (2020)

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
por: Tomelleri, Alessandro, et al.
Publicado: (2018)

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement
por: De Luca, Giacomo, et al.
Publicado: (2021)

A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)
por: Campochiaro, Corrado, et al.
Publicado: (2021)

Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry
por: Vitale, Antonio, et al.
Publicado: (2022)

One year later: The case of tocilizumab in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Cardiovascular involvement in Erdheim–Chester diseases is associated with myocardial fibrosis and atrial dysfunction
por: Palmisano, Anna, et al.
Publicado: (2023)

Myocarditis: An Interleukin-1-Mediated Disease?
por: De Luca, Giacomo, et al.
Publicado: (2018)

Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
por: Tomelleri, Alessandro, et al.
Publicado: (2022)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
por: Campochiaro, Corrado, et al.
Publicado: (2020)

Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
por: Galozzi, Paola, et al.
Publicado: (2018)

Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease
por: Vitale, Antonio, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

Canakinumab and mycophenolate mofetil in managing proteinuria/renal amyloidosis secondary to adult-onset Still’s disease
por: Feng, Jin, et al.
Publicado: (2023)

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

The conundrum of interleukin-6 blockade in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2020)

Correction to: Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts
por: Colafrancesco, Serena, et al.
Publicado: (2020)

Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure
por: Cavalli, Giulio, et al.
Publicado: (2017)

Multimodal Chorioretinal Imaging in Erdheim-Chester Disease
por: Sacconi, Riccardo, et al.
Publicado: (2020)

Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India
por: Misra, Durga Prasanna, et al.
Publicado: (2022)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
por: Cavalli, Giulio, et al.
Publicado: (2021)

Correction to: Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?
por: Benedetti, Francesco, et al.
Publicado: (2021)

Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease in the U.S. Real-World Settings
por: Hur, Peter, et al.
Publicado: (2021)

Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease
por: Shaul, Eliana, et al.
Publicado: (2022)

Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave
por: Palumbo, Diego, et al.
Publicado: (2021)

Cardiac magnetic resonance findings in acute and post‐acute COVID‐19 patients with suspected myocarditis
por: Palmisano, Anna, et al.
Publicado: (2022)

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab
por: Ghannam, Khetam, et al.
Publicado: (2021)

Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses
por: Dunger-Baldauf, Cornelia, et al.
Publicado: (2022)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response
por: Vitale, Antonio, et al.
Publicado: (2019)

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
por: De Luca, Giacomo, et al.
Publicado: (2020)

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
por: Cavalli, Giulio, et al.
Publicado: (2020)

Effect of anakinra in COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness
por: Cavalli, Giulio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lg4apda0kk695oapd8nvutnf81